The FDA cleared orforglipron for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, based on the ATTAIN clinical program which showed placebo-adjusted weight loss of 7.5% to 11.2% in non-diabetics (ATTAIN-1) and 5.1% to 9.6% in diabetics at different doses, along with the expected glycaemic benefits (ATTAIN-2)
Facilita il trasporto degli acidi grassi nei mitocondri per la produzione di energia, mentre la sua capacit di attraversare la barriera ematoencefalica la rende efficace per migliorare concentrazione e lucidit mentale
crassa The heterologous expression of the genes for the fullL-carnitine biosynthesis cascade by the plasmid pTrc99A-TML2Car revealed L-carnitine production not only from the supplemented precursor TML, but also without it, providing evidence of de novo L-carnitine biosynthesis (Figure 5)
Advanced Nutrition and Human Metabolism, 3rd ed
weight loss has been a welcome bonus
Individual response varies based on digestive health and genetic factors